What is HC Wainwright’s Forecast for KYTX FY2025 Earnings?

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – HC Wainwright lowered their FY2025 EPS estimates for shares of Kyverna Therapeutics in a report issued on Wednesday, August 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($3.60) for the year, down from their previous forecast of ($3.56). HC Wainwright currently has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q4 2025 earnings at ($0.82) EPS and FY2026 earnings at ($3.61) EPS.

Kyverna Therapeutics Stock Down 0.8%

Shares of KYTX stock opened at $3.51 on Friday. The stock has a market cap of $151.79 million, a price-to-earnings ratio of -0.95 and a beta of 3.05. Kyverna Therapeutics has a fifty-two week low of $1.78 and a fifty-two week high of $8.78. The firm’s 50 day moving average price is $3.44 and its two-hundred day moving average price is $2.79.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.03.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KYTX. Gilead Sciences Inc. acquired a new position in shares of Kyverna Therapeutics during the fourth quarter worth $15,432,000. Jacobs Levy Equity Management Inc. lifted its position in shares of Kyverna Therapeutics by 2,225.0% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 461,959 shares of the company’s stock worth $1,728,000 after purchasing an additional 442,090 shares in the last quarter. Peapod Lane Capital LLC acquired a new position in shares of Kyverna Therapeutics during the first quarter worth $765,000. TD Asset Management Inc lifted its position in shares of Kyverna Therapeutics by 179.5% during the second quarter. TD Asset Management Inc now owns 252,196 shares of the company’s stock worth $774,000 after purchasing an additional 161,954 shares in the last quarter. Finally, Integral Health Asset Management LLC lifted its position in shares of Kyverna Therapeutics by 75.0% during the fourth quarter. Integral Health Asset Management LLC now owns 350,000 shares of the company’s stock worth $1,309,000 after purchasing an additional 150,000 shares in the last quarter. 18.08% of the stock is owned by institutional investors and hedge funds.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.